Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
0.67 | |
1.05 | |
- | |
0.75 | |
1.22 | |
0.64-1.06 | |
34 122 K | |
45 496 K | |
0 | |
0.675 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: